Antimony

Summary

Antimony (CHEMBL4297652) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including peripheral neuropathy and cutaneous leishmaniasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297652
Name	Antimony
Type	Small molecule
Max phase	3

Also known as: Antimony, Antimony black, Antimony element, elemental, C.I. 77050, Metallic antimony, Prepared metallic antimony, SB, Stibium metallicum, ANTIMONY

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
peripheral neuropathy	3	MONDO:0005244	EFO:0003100
cutaneous leishmaniasis	2	MONDO:0005446	EFO:0005046

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00233545	PHASE2	COMPLETED	Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
NCT01380301	PHASE2	TERMINATED	Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony
NCT00469495	Not specified	COMPLETED	Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).